Skip to main content Back to Top
Advertisement

10/16/2025

Furosemide Injection

Products Affected - Description

    • Furosemide injection, Hikma, 10 mg/mL, 10 mL vial, 10 count, NDC 00143-9157-10
    • Furosemide injection, Hikma, 10 mg/mL, 100 mL vial, 1 count, NDC 00143-9159-01
    • Furosemide injection, Hikma, 10 mg/mL, 4 mL vial, 10 count, NDC 00143-9156-10
    • Furosemide injection, Hikma, 10 mg/mL, 50 mL vial, 1 count, NDC 00143-9158-01
    • Furosemide injection, Pfizer, 10 mg/mL, 4 mL vial, 25 count, NDC 00409-6102-04
    • Furosemide injection, Sagent, 10 mg/mL, 10 mL vial, 25 count, NDC 25021-0311-10
    • Furosemide injection, Sagent, 10 mg/mL, 2 mL vial, 25 count, NDC 25021-0320-02
    • Furosemide injection, Sagent, 10 mg/mL, 4 mL vial, 25 count, NDC 25021-0320-04

Reason for the Shortage

    • American Regent is not actively marketing furosemide injection.
    • Amneal discontinued furosemide injection.
    • Avenacy has furosemide injection available.
    • Avet Pharmaceuticals has furosemide injection available.
    • Baxter has furosemide injection available.
    • Devatis has furosemide injection available.
    • Eugia has furosemide injection available.
    • Fresenius Kabi has furosemide injection available.
    • Hikma did not provide a reason for the shortage.
    • Meitheal has furosemide injection available.
    • Pfizer has furosemide injection on shortage due to manufacturing delays.
    • Sagent did not provide a reason for the shortage.

Available Products

    • Furosemide injection, Avenacy, 10 mg/mL, 10 mL vial, 25 count, NDC 83634-0302-10
    • Furosemide injection, Avenacy, 10 mg/mL, 2 mL vial, 25 count, NDC 83634-0302-02
    • Furosemide injection, Avenacy, 10 mg/mL, 4 mL vial, 25 count, NDC 83634-0302-04
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 10 mL vial, 25 count, NDC 23155-0476-41
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 2 mL vial, 25 count, NDC 23155-0473-41
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 4 mL vial, 25 count, NDC 23155-0474-41
    • Furosemide injection, Baxter, 10 mg/mL, 10 mL vial, 25 count, NDC 36000-0284-25
    • Furosemide injection, Baxter, 10 mg/mL, 2 mL vial, 25 count, NDC 36000-0282-25
    • Furosemide injection, Baxter, 10 mg/mL, 4 mL vial, 25 count, NDC 36000-0283-25
    • Furosemide injection, Devatis, 10 mg/mL, 10 mL vial, 25 count, NDC 73043-0024-01
    • Furosemide injection, Devatis, 10 mg/mL, 2 mL vial, 25 count, NDC 73043-0022-01
    • Furosemide injection, Devatis, 10 mg/mL, 4 mL vial, 25 count, NDC 73043-0023-01
    • Furosemide injection, Eugia US, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0324-25
    • Furosemide injection, Eugia US, 10 mg/mL, 2 mL vial, 25 count, NDC 55150-0322-25
    • Furosemide injection, Eugia US, 10 mg/mL, 4 mL vial, 25 count, NDC 55150-0323-25
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0280-10
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0280-02
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 4 mL vial, 25 count, NDC 63323-0280-04
    • Furosemide injection, Hikma, 10 mg/mL, 2 mL vial, 25 count, NDC 00143-9155-25
    • Furosemide injection, Meitheal Pharmaceuticals, 10 mg/mL, 10 mL vial, 25 count, NDC 71288-0205-11
    • Furosemide injection, Meitheal Pharmaceuticals, 10 mg/mL, 2 mL vial, 25 count, NDC 71288-0205-03
    • Furosemide injection, Meitheal Pharmaceuticals, 10 mg/mL, 4 mL vial, 25 count, NDC 71288-0205-05
    • Furosemide injection, Pfizer, 10 mg/mL, 10 mL vial, 25 count, NDC 00409-6102-10
    • Furosemide injection, Pfizer, 10 mg/mL, 2 mL vial, 25 count, NDC 00409-6102-02
    • Furosemide injection, Sagent, 10 mg/mL, 10 mL vial, 25 count, NDC 25021-0320-10
    • Furosemide injection, Sagent, 10 mg/mL, 2 mL vial, 25 count, NDC 25021-0311-02
    • Furosemide injection, Sagent, 10 mg/mL, 4 mL vial, 25 count, NDC 25021-0311-04

Estimated Resupply Dates

    • Sagent has short-dated furosemide 10 mg/mL 10 mL vials (NDC 25021-0311-10) available with an expiration date of November 2025. The 2 mL vials (NDC 25021-0320-02) and 4 mL vials (NDC 25021-0320-04) on allocation.
    • Pfizer has furosemide 10 mg/mL 4 mL vials available in limited supply.
    • Hikma has furosemide 10 mg/mL 4 mL vials on back order and the company estimates a release date of early-November 2025. There are short-dated 10 mL, 50 mL, and 100 mL vials available with an expiration date of February 2026 for the 10 mL vials, March 2026 for the 50 mL vials, and < May 2026 for the 100 mL vials.

Updated

Updated October 16, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 19, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT